PSK Pharma has registered a new drug product, Saxagliptin PSK (INN: saxagliptin), expanding its portfolio for the treatment of type 2 diabetes mellitus. The product is available in tablet form in 2.5 mg and 5 mg dosages and is indicated for adults aged 18 years and older as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.
According to Evgeniya Shapiro, General Director of PSK Pharma, Saxagliptin PSK is the third gliptin-class product in the company’s diabetes portfolio and is included in the List of Vital and Essential Drugs (VED).
“Based on publicly available data, more than 200,000 packs of saxagliptin were sold in the public procurement segment last year. At our manufacturing site located in the Dubna Special Economic Zone, we are capable of producing up to 1.9 million packs per year, which allows us to fully meet market demand even in the event of potential growth over the coming years. Overall, the company’s strategy is focused on expanding its range of medicines for the treatment of socially significant diseases, including type 2 diabetes,” said Evgeniya Shapiro.
The number of patients with diabetes continues to grow across all age groups; however, therapeutic approaches to the disease are also evolving. Gliptins belong to a class of modern oral antidiabetic agents. Saxagliptin can be used both as monotherapy and as part of combination therapy for various forms of type 2 diabetes. It is considered an optimal partner for metformin in initial combination therapy, providing reliable glycemic control without an increased risk of hypoglycemia.